Efficacy of a prostaglandin analogue in reproduction in the anestrous mare

A prostaglandin F analogue was studied in anestrous mares: a dose-response study; a study in mares presumed pregnant; and a field evaluation of effective doses in breeding establishments. A dose of 2.0mg given by single subcutaneous injection to mares with initial plasma progesterone levels greater than 1.0ng/ml, caused luteolysis on the basis of decline in plasma progesterone concentrations. Follicle maturation leading to ovulation, accompanied by estrus, was observed, and fertility at mating either by natural service or artificial insemination was satisfactory. A dose of 1.0mg was generally effective for luteolysis, but pregnancy rates were lower than after 2.0mg. A proportion of mares which had less than 1.0mg of plasma progesterone at the time of injection ovulated and became pregnant.     

Efficacy of a prostaglandin analogue in reproduction in the cycling mare.

A prostaglandin F analogue caused luteolysis in normal cycling non-lactating mares, and lactating mares (treated after the foal estrus). Effective doses ranged from 1.0 to 4.0mg given as a single subcutaneous injection 8–10 days after ovulation. A dose of 0.5mg was ineffective, hence the dose-response relationship was steep, indicative of a quantal type of response. Mares usually returned to estrus within 2–4 days and ovulated by 7 days after treatment. Mares bred naturally or by artificial insemination at the induced estrus and ovulation were fertile. The compound was without side-effects, and hence should be of value in manipulating the estrous cycle of the mare.     

Induction of parturition in the pig using a new prostaglandin analogue (K11941)

Eighty seven sows, taken from a herd whose mean gestation length was 116 days, were allotted at random on day 114 of gestation to one of five treatment groups as follows: (1) 175 mug prostaglandin analogue (closprostenol I.C.I. Ltd) (2) 1 mg K11941 (alfaprostol VETEM Ltd), (3) 2 mg K11941, (4) 3 mg K11941 (5) 2 ml saline (control). All prostaglandin analogues induced parturition significantly earlier than controls (P < 0.05), but there were no differences between any of the prostaglandin treatments in the interval to birth of the first piglet (P > 0.05). The mean intervals to parturition were 24.6, 22.3, 24.9, 30.7 and 53.0 hours for treatments 1, 2, 3, 4 and 5 respectively. Almost two-thirds of treated sows farrowed during the working period of the day following injection compared with a small proportion of control animals. Induction of parturition had no effect on birth weight, piglet survival to 3 weeks or on subsequent weaning to service interval in treated sows. Results show that this new analogue of prostaglandin (K11941) is effective in inducing farrowing in the sow.     

Luteolytic potencin in a novel prostaglandin analogue

Estrus induction in cycling sows with exogenous prostaglandin is hindered by the extended refractory period and resistance of swine to the luteolytic action of PG's. The luteolytic potency of a novel PGF_2α analogue, Schering ZK 71677, was assessed at four different dosages in chronically cannulated cycling swine. Dosages totalling 1, 1.5, 3 and 10 mg of ZK 71677 were split into two injections given intramuscularly on day 13 of the estrous cycle. Onset of behavioural estrus and serum levels of progesterone and PGF metabolite were monitored. The three lowest doses did not advance estrus but did cause a transitory decline in serum progesterone concentration on day 13. The 10 mg level advanced estrus in three of four sows although the overall mean cycle length did not differ from pretreatment cycles (18.5 ± 1.3 vs 21.3 ± 0.6 days). Progesterone values droppd steadily in all four sows in the 10 mg treatment group. No level of ZK 71677 affected serum levels of PGF metabolite. The highest level tested of PGF_2α analogue ZK 71677 elicited an uninterrupted decline in serum progesterone concentrations but was inconsistent in its ability to promote early onset of behavioural estrus in swine.     

Luteolysis and cycle synchronization with a new prostaglandin analog for artificial insemination in the mare

Over a period of three years, 165 cyclic or anestrous Hanoverian mares received 177 treatments with 2, 3 or 4 mg of a novel luteolytic prostaglandin analog, K 11941. Heat and ovulations, indicating luteolysis, were observed after an average of 3.98 and 7.62 days, respectively, in 88.04% of 142 treated cyclic, postpartum and anestrous mares, and mares after an early loss of the conceptus. All doses tested were effective in inducing luteolysis as confirmed by determination of progesterone blood levels in samples collected daily, in 70 of 80 mares studied (87.5%). Attempts to achieve control of the cycle by various methods revealed that with K 11941 given once or twice, alone or in combination with hCG and/or an GnRH analog (Hoe 766), one can effectively concentrate estrus periods and follicular growth patterns, but can neither synchronize nor concentrate ovulations. Since most of the mares treated were confirmed problem mares, the pregnancy rate of 40.0% from first insemination at drug induced estrus, was regarded as satisfactory when compared to a pregnancy rate of 43.8% obtained with natural breeding in the same population. No drug related clinical signs of side-effects were observed.     

Parturition control in sows with a prostaglandin analogue (alfaprostol)

The objective of this study was to determine the dose of alfaprostol (18, 19, 20-trinor-17-cyclohexyl-13, 14 didehydro-PGF(2)alpha-methylester) and the day of administration most effective in inducing sows to farrow during normal working hours (0700 to 1700). One-hundred forty multiparous crossbred sows, taken from a herd whose mean gestation length was 114.3 days, were assigned to one of five treatment groups: 1) control vehicle-propylene glycol, 2) 0.5 mg alfaprostol (AP). 3) 1 mg AP, 4) 2 mg AP and 5) 3 mg AP. Sows received an intramuscular injection of AP between 0800 and 0830 on either day 111, 112 or 113 of gestation. Parameters studied included interval from injection to birth of first pig, farrowing interval, total number of pigs born, number born alive, average birth weight, percent stillborn, interval from weaning to next estrus and number born alive next litter. The mean intervals from injection to the birth of the first pig were 55.2 +/- 7.1; 41.1 +/- 5.1; 29.6 +/- 4.0; 24.3 +/- 1.1; 24.8 +/- 0.9 h for groups 1, 2, 3, 4 and 5, respectively (P<0.05). The percentage of sows that farrowed during normal working hours (23 to 33 h after injection) for groups 1, 2, 3, 4 and 5 were 15, 53, 60, 77 and 70%, respectively. Average birth weights (kg) for treatment groups 1, 2, 3, 4 and 5 were 1.54 +/- 0.05; 1.65 +/- 0.05; 1.59 +/- 0.05; 1.54 +/- 0.05 and 1.42 +/- 0.05, respectively (P<0.05). Mean differences in total number of pigs born and number born alive were also statistically significant (P<0.05) but stillbirth rate was not different (P>0.05) among treatment groups. These results indicate that a single injection of 1, 2 or 3 mg of alfaprostol will successfully induce parturition the following day in a majority of the treated sows.     

Effect of phenylbutazone (PBZ) on luteolysis in the mare induced by uterine biopsy

Uterine biopsy in the mare on day 4 post-ovulation causes an acute inflammatory reaction which results in premature luteolysis. In this study, seven mares (4 to 6 years of age) were used in a switchback experimental design to test the hypothesis that in the mare parenterally administered PBZ will block luteolysis induced by uterine biopsy on day 4 post-ovulation. All mares were allowed two normal estrous cycles (range 18 to 24 days). On the first day of estrus of the third estrous cycle each mare was intravenously given 2 grams PBZ (treatment) or 10 ml 0.9% saline (control) daily until signs of estrus were exhibited. The day of ovulation (day 0) was determined by rectal palpation and subsequently verified by peripheral plasma progesterone concentrations. On day 4 following ovulation all mares were subjected to uterine biopsy, and subsequent estrus detection was performed daily using an andro-genized gelding. A total of 19 estrous cycles (ten for PBZ treatment and nine for controls) were evaluated. Mean number of days (+/-SE) from uterine biopsy to induced estrus was 5.00+/-0.16 for control cycles and was significantly different (P<0.025) when compared with 9.20+/-0.34 days for treatment cycles. Results of this study suggest that PBZ can block luteolysis in the mare induced by uterine biopsy on day 4 post-ovulation, possibly as a result of accumulating PBZ in acutely inflamed uterine tissue and inhibiting prostaglandin synthesis.     

Failure of the prostaglandin F2 alpha analogue, cloprostenol, to induce functional luteolysis in the olive baboon (Papio cynocephalus anubis)

The prostaglandin F2 alpha analogue, cloprostenol, which is an effective luteolytic agent in the common marmoset, was administered intramuscularly to olive baboons to determine if it possessed luteolytic properties in this species. The results showed that functional luteolysis was not induced when cloprostenol was administered during the mid- to late luteal phase or during early pregnancy.     

Induction of parturition in crossbred sows with cloprostenol,an analogue of prostaglandin F2α

Forty-six crossbred sows were treated with a single intramuscular injection of 175 μg of cloprostenol on day 110, 112 or 113 of gestation and compared with 46 control animals farrowing naturally during the same period. Of the treated animals, 96% farrowed within 48 h. The mean time to the induced farrowing was 28 ± 1.2 h with 64% of the farrowings occurring during daylight hours. Piglet mortality was greater for farrowings induced at day 110 than for 112 or 113 days of gestation. Since the mean length of gestation for natural farrowings for untreated control sows was 115 ± 0.9 days, it may be concluded that farrowings could safely be induced within 2–3 days of the average expected farrowing date for the herd. For precise timing of treatment, the average gestation length for individual herds should be pre-determined and accurate breeding records are needed.     

Administration of a nitric oxide synthase inhibitor counteracts prostaglandin F2-induced luteolysis in cattle

The objective of this study was to determine whether nitric oxide (NO) is produced locally in the bovine corpus luteum (CL) and whether NO mediates prostaglandin F2alpha (PGF2alpha)-induced regression of the bovine CL in vivo. The local production of NO was determined in early I, early II, mid, late, and regressed stages of CL by determining NADPH-d activity and the presence of inducible and endothelial NO synthase immunolabeling. To determine whether inhibition of NO production counteracts the PGF2alpha-induced regression of the CL, saline (10 ml/h; n = 10) or a nonselective NOS inhibitor (Nomega-nitro-l-arginine methyl ester dihydrochloride [L-NAME]; 400 mg/h; n = 9) was infused for 2 h on Day 15 of the estrous cycle into the aorta abdominalis of Holstein/Polish Black and White heifers. After 30 min of infusion, saline or cloprostenol, an analogue of PGF2alpha (aPGF2alpha; 100 microg) was injected into the aorta abdominalis of animals infused with saline or L-NAME. NADPH-diaphorase activity was present in bovine CL, with the highest activity at mid and late luteal stages (P < 0.05). Inducible and endothelial NO synthases were observed with the strongest immunolabeling in the late CL (P < 0.05). Injection of aPGF2alpha increased nitrite/nitrate concentrations (P < 0.01) and inhibited P4 secretion (P < 0.05) in heifers that were infused with saline. Infusion of L-NAME stimulated P4 secretion (P < 0.05) and concomitantly inhibited plasma concentrations of nitrite/nitrate (P < 0.05). Concentrations of P4 in heifers infused with L-NAME and injected with aPGF2alpha were higher (P < 0.05) than in animals injected only with aPGF2alpha. The PGF2alpha analogue shortened the cycle length compared with that of saline (17.5 +/- 0.22 days vs. 21.5 +/- 0.65 days P < 0.05). L-NAME blocked the luteolytic action of the aPGF2alpha (22.6 +/- 1.07 days vs. 17.5 +/- 0.22 days, P < 0.05). These results suggest that NO is produced in the bovine CL. NO inhibits luteal steroidogenesis and it may be one of the components of an autocrine/paracrine luteolytic cascade induced by PGF2alpha.     

Induction of luteolysis in mares by ultrasound-guided intraluteal treatment with PGF2alpha.

To evaluate the technique of ultrasound-guided luteal injection in mares, PGF2alpha was administered under ultrasound guidance to horse mares (n = 7 to 9 per group) on Day 9 postovulation via either a systemic (i.m.; zero, 0.01, 0.1, or 5 mg/dose) route or a local intraluteal (i.l.; zero, 0.01 or 0.1 mg/dose) route. The luteolytic efficacy of each treatment was determined based on post-treatment decreases in progesterone concentration, interval to uterine edema (IE) and interovulatory interval (IOI). Local administration of PGF2alpha directly into the CL consistently induced luteolysis, at doses up to 50-fold lower than the lowest effective systemic dose. Significant decreases in IOI and IE occurred in mares treated with 5 mg PGF2alpha i.m. or 0.1 mg PGF2alpha i.l., but did not occur in mares treated with 0.1 or 0.01 mg PGF2alpha i.m., 0.01 mg PGF i.l., vehicle i.l. or vehicle i.m.. Progesterone concentrations were reduced to less than 10% of pretreatment values by two days post treatment in mares treated with 5 mg PGF2alpha i.m. or 0.1 mg PGF2alpha i.l.. PGF2alpha doses of 0.1 mg i.m. and 0.01 mg i.l. were associated with smaller but significant progesterone decreases (to 66% and 46% of pre-treatment values, respectively) by two days post treatment. Progesterone values after administration of i.l. vehicle did not differ from pre-treatment values by two days post treatment, but were significantly lower (53% of pre-treatment values) by four days post treatment. Intramuscular treatment with vehicle or 0.01 mg of PGF2alpha did not significantly reduce progesterone concentrations below pretreatment values. Overall, the minimum effective luteolytic dose of PGF2alpha given intraluteally was between 0.01 and 0.1 mg. Based on the results of this study, ultrasound-guided i.l. injection appears to be a repeatable method for studying the direct effect of other chemicals on luteal function. However, the current procedure carries some risk, since three i.l. injections were associated with ovarian abscesses.     

Time of ovulation in ewes after treatment with a prostaglandin F-2alpha analogue

Treatment of 18 cyclic Clun Forest ewes with two i.m. injections of ICI 80,996, given 9 days apart and without reference to stage of the oestrous cycle, synchronized ovulation in all ewes at a mean time interval of 73.1 +/- 1.6 (s.e.m.) h from the second injection. The interval from the LH peak to ovulation was 22.6 +/- 0.7 h and this is comparable to previously reported gigures for a natural oestrus.     

Studies on the mechanism of action of prostaglandin F2 alpha induced luteolysis in rats

The effects of prostaglandin F2 alpha (PGF2 alpha) administration on the utilization of low density lipoprotein (LDL) and progesterone secretion were examined in dispersed luteal cells from rat ovaries. Immature rats were rendered pseudopregnant with administration of pregnant mare serum gonadotropin and human chorionic gonadotropin. Animals were sacrificed at different times after PGF2 alpha (5 mg/kg) or vehicle administration on day-5 of pseudopregnancy. Administration of PGF2 alpha in vivo decreased human chorionic gonadotropin (hCG) binding to luteal cell membranes in vitro but enhanced binding of LDL. Utilization of labelled cholesterol for steroid synthesis from reconstituted LDL [(3H)-CL-LDL] by dispersed luteal cells was enhanced following PGF2 alpha administration. This suggests that the LDL pathway is not suppressed during prostaglandin induced luteolysis. Progesterone and total progestin secretion in response to N6-2'-0-Dibutyryladenosine 3'5'-cyclic monophosphate (cAMP) was decreased at 2, 4 and 24 hours following PGF2 alpha administration demonstrating a post-cAMP defect in steroidogenesis. Addition of the hydroxylated sterols, 20 or 25-OH cholesterol as substrate stimulated progesterone secretion in vehicle treated rats in a dose dependent fashion with 20-OH cholesterol being more potent. Progesterone secretion in response to stimulation with luteinizing hormone (LH) and cAMP from vehicle treated rats was less than that observed with 20 or 25-OH cholesterol, indicating that endogenous substrate may be a limiting factor in steroid synthesis. The maximal capacity of luteal tissue to produce progestins following PGF2 alpha administration was determined with 20-OH cholesterol as the substrate. The results suggest that the post-cAMP defect at 4 hours following PGF2 alpha administration may be due to failure of the cells to mobilize endogenous cholesterol. However at 24 hours following PGF2 alpha administration the decreased ability of luteal cells to convert cholesterol to pregnenolone may contribute to decreased progesterone synthesis.     

Control of estrus in dairy cows with a synthetic analogue of prostaglandin F2 alpha

Trials were carried out on 1184 dairy cows calved at least six weeks before treatment and 255 heifers to determine effectiveness of the prostaglandin analogue, cloprostenol to control estrus. In trial 1, following two injections of cloprostenol given 12 days apart, there was no difference in calving rate following AI either at 72 and 96 hr after treatment (71 163 ) or at a detected estrus (53 118 ) compared to control cows bred at estrus (54 110 ). In trial 2, treated cows were injected once after 5 to 7 days of estrous detection and AI. The calving rate following AI either at 72 and 96 hr after cloprostenol (46 100 ) or at a detected estrus (39 71 ) was similar to that in control cows bred at estrus (45 86 ). In trial 3, cows were bred at a detected estrus after the first cloprostenol injection. Twelve days after this injection, cows not bred were given a second injection and bred 72 and 96 hr later. The calving rate in treated cows bred at estrus after the first injection (66 138 ) was similar to calving rate in controls (55 95 ). However, calving rate in cows given a second injection and bred 72 and 96 hr later was significantly (P angle 0.05) lower (30 98 ). Similar results were obtained in heifers, except calving rate in trial 3 after the second cloprostenol injection was not reduced.     

Effects of prostaglandin F2 alpha-induced luteolysis on the populations of cells in the ovine corpus luteum

Receptors for prostaglandin (PG) F2 alpha in the ovine corpus luteum are localized on large steroidogenic luteal cells. Therefore, it was hypothesized that during luteolysis, the first demonstrable effects of PGF2 alpha would occur in the population of large luteal cells. To test this hypothesis, the numbers and sizes of large and small luteal cells, fibroblasts, capillary endothelial cells, and pericytes were determined in corpora lutea collected 12, 24, or 36 h (6 animals/group) following administration of PGF2 alpha on Day 10 postestrus and from untreated ewes on Days 10 and 12 postestrus. The numbers and sizes of luteal cells were determined after enzymatic dissociation of the luteal tissue into single cell suspensions and by morphometric analysis of luteal slices. Serum levels of progesterone decreased (p less than 0.05) within 12 h of treatment, indicating that luteolysis was induced. Recovery of the two types of steroidogenic luteal cells following enzymatic dissociation was different (p less than 0.05). Recovery of both steroidogenic cell types decreased with time after PGF2 alpha treatment, suggesting that they had become more fragile. As determined by morphometry, the number of large luteal cells was not different at any time point examined; however, by 36 h after treatment, the average diameter of large luteal cells had decreased (p less than 0.05). In contrast, by 24 h after treatment, there was a decrease in the number of small luteal cells (p less than 0.05) but no change in their diameter.(ABSTRACT TRUNCATED AT 250 WORDS)     

Induction of labour with a sustained-release prostaglandin E2 vaginal pessary.

A new polymer vaginal pessary providing sustained constant release of prostaglandin E2 was administered to 66 patients before planned induction of labour. Effective ripening of the unfavourable cervix was achieved in each of 18 primigravidas, in eight of whom labour was initiated without further treatment. When the cervix was moderately favourable the need for orthodox induction of labour was obviated in 16 out of 23 primigravidas and 21 out of 23 multigravidas. This method of sustained release of prostaglandin E2 is simple and convenient and readily acceptable to the patient; it is an important step in the development of non-invasive methods of inducing labour.